secwatch.observer — SEC 8-K summary
======================================

Issuer:     RECURSION PHARMACEUTICALS, INC. (RXRX)
CIK:        0001601830
Form:       8-K
Filed at:   2023-08-08T23:59:59+00:00
Accession:  0001601830-23-000056
Event type: other_material
Sentiment:  positive
Materiality: 0.85
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Recursion predicts protein targets for 36B compounds; Q2 net loss $76.7M, revenue $11M
--------------------------------------------------------------------------------

- Predicted protein targets for ~36B compounds in Enamine REAL Space, evaluating 2.8 quadrillion target-compound pairs using NVIDIA DGX Cloud.
- Q2 2023 revenue $11.0M (up from $7.7M); net loss $76.7M (up from $65.6M); cash $405.9M, excluding $50M NVIDIA investment.
- Received $50M investment from NVIDIA; collaboration to build AI foundation models for drug discovery.
- Appointed David Mauro as CMO and Nathan Hatfield as Chief Legal Officer.
- First Phase 1 data readout for REC-3964 expected in Q3 2023; multiple pipeline catalysts through 2024-2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1601830/000160183023000056/0001601830-23-000056-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1601830/000160183023000056/rxrx-20230808.htm
  HTML page:      https://secwatch.observer/filing/0001601830-23-000056

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer